Abstracts tagged "Arthritis and cancer treatments"

Abstract Number: 355 • 2018 ACR/ARHP Annual Meeting
Association of HLA-DRB1 Shared Epitope Alleles with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Laura C. Cappelli¹, Mehmet Tevfik Dorak², Clifton O. Bingham III³ and Ami A. Shah¹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Kingston University London, Kingston upon Thames, United Kingdom, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICI), an important type of cancer therapy, can cause adverse events through immune activation. Inflammatory arthritis (IA) due to ICI treatment…
Abstract Number: 1866 • 2017 ACR/ARHP Annual Meeting
Use of Aromatase Inhibitors and Risk of Arthritis and Musculoskeletal Problems Among Taiwanese Women with Breast Cancer: A Nationwide Claims Analysis
Hsu-Chih Chien^1,2,3, Wei-Hsuan Lo-Ciganic⁴, C. Kent Kwoh⁵ and Yea-Huei Kao Yang⁶, ¹, Department of Medicine, University of Arizona, Tucson, AZ, Division of Rheumatology, Tucson, AZ, ²College of Medicine and Health Outcome Research Center, National Cheng Kung University, Tainan, Taiwan, Institute of Clinical Pharmacy and Pharmaceutical Sciences, Tainan, Taiwan, ³University of Arizona Arthritis Center, Tucson, AZ, ⁴Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, Associate professor, TUCSON, AZ, ⁵University of Arizona, Tucson, AZ, ⁶College of Medicine, National Cheng Kung University, Institute of Clinical Pharmacy and Pharmaceutical Science, Taian, Taiwan
Background/Purpose: Asian women accounted for more than 40% of incident breast cancer (BC) worldwide. While aromatase inhibitors (AIs) significantly reduce recurrence of breast cancer (BC)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].